Keywords: merck, kgaa/imclone, clarify, erbitux, deal, kgaa, imclone
Merck KGaA/ImClone clarify Erbitux deal
Article | 27 May 2002
Merck KGaA and ImClone, its US partner for Erbitux (cetuximab), itsantibody-based treatment for irinotecan-refractory colorectal cancer, have reiterated the German ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
